Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Oncology
•
Cervical Cancer
How would you approach unresectable pelvic side wall recurrence in cervical cancer with previous definitive chemoradiation?
Would you consider SBRT or brachytherapy?
Answer from: Radiation Oncologist at Community Practice
I would start with palliative chemo and if good response, plan for SBRT for residual disease with the dose based on OAR.
Comments
Radiation Oncologist at UAB Department of Radiation Oncology
I agree with the above comments. This is one of th...
Radiation Oncologist at Baylor College of Medicine
What dose constraints have you been following for ...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
Ling et al., PMID 31150869
Radiation Oncologist at Emeritus Professor
The definition of unresectable pelvic sidewall rec...
3340
3344
3346
3372
Sign in or Register to read more
8198
Related Questions
How would you manage a recurrent cervical cancer previously treated with vaginal cuff brachytherapy and has had a complete response to chemo-immunotherapy?
How do you treat a locally advanced cervix cancer in a patient who declines brachytherapy?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
How would you manage a cervical cancer patient with bulky PA LNs with direct extension and/or invasion into the lumbar vertebral bodies?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
How would you manage a female in her 40s with stage III cervical cancer with hydronephrosis and Crohn's disease?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
In patients getting concurrent chemo-immunotherapy for locally advanced cervix cancer, would you hold immunotherapy during the 2.5-3 weeks of brachytherapy?
I agree with the above comments. This is one of th...
What dose constraints have you been following for ...
Ling et al., PMID 31150869
The definition of unresectable pelvic sidewall rec...